The short answer
Obesity and insulin resistance disrupt ovulatory function, and polycystic ovary syndrome is the clearest case. Reducing weight and improving insulin sensitivity can restore ovulation. Salamun and colleagues reported liraglutide increasing IVF pregnancy rates in obese PCOS women with poor response to first-line treatment.
Key facts
- Mechanism
- Improved insulin sensitivity, weight reduction
- Population most affected
- PCOS
- Pilot randomised study
- Salamun 2018 (PMID 29703793)
- Journal
- Eur J Endocrinol, July 2018
- Compound studied
- Liraglutide
- Setting
- IVF, poor response to first-line treatment
Why insulin resistance disrupts ovulation
High circulating insulin acts on the ovary and alters steroid production, raising androgen output and disturbing the hormonal sequence that drives follicle maturation and release. It also lowers sex hormone-binding globulin, which raises free androgen further. The result is disrupted ovulatory cycling, and it is a hormonal consequence of the metabolic state rather than a primary ovarian defect.
Why PCOS is the clearest case
Polycystic ovary syndrome couples reproductive and metabolic disturbance in the same condition: irregular or absent ovulation alongside insulin resistance in a large proportion of those affected. That coupling is why an intervention acting on the metabolic side can change the reproductive side, and why this population appears repeatedly in the literature.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the 2018 study examined
Salamun and colleagues published a pilot randomised study in the European Journal of Endocrinology examining liraglutide and IVF pregnancy rates in obese women with PCOS who had responded poorly to first-line reproductive treatment. A pilot randomised study is early-stage evidence in a defined and difficult population, not a general statement about fertility.
Why the effect is not attributable to the drug alone
The same attribution problem that runs through this entire class. Weight loss itself improves ovulatory function and has done so long before these compounds existed, through diet and surgery. Whether an incretin does anything beyond causing the weight loss is a separate question, and one this design cannot separate.
Why this matters even to people not seeking pregnancy
Because a return of ovulation is a return of fertility whether or not it was wanted. Someone whose cycles were irregular or absent may have been relying on that as a practical matter. Restoring ovulation changes that circumstance without any announcement, which is the substance of the convergence described in the companion article on this site.
What this concerns
Licensed medicines studied in registered trials under clinical supervision. Nothing supplied on this site is a GLP-1 receptor agonist, affects fertility, or has any place in reproductive care. These findings describe medicines, and decisions about fertility belong with a clinician.
Frequently asked questions
What did the 2018 study find?
It was a pilot randomised study of liraglutide and IVF pregnancy rates in obese PCOS women with poor response to first-line treatment. It is early-stage evidence in a specific population.
Is the effect from the drug or the weight loss?
Not separable. Weight loss alone improves ovulatory function, and the two occur together in the same participants.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSalamun V et al., Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol 2018 (PMID 29703793)pubmed.ncbi.nlm.nih.gov
- PubMedSaad Alfaiz A et al., GLP-1 receptor agonists and preconception planning. Ann Med Surg 2025 (PMID 41377305)pubmed.ncbi.nlm.nih.gov
- PubMedHviid KVR et al., Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes. Hum Reprod Open 2026 (PMID 41852577)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Restored Fertility and Reduced Contraceptive AbsorptionOne effect makes conception more likely; another can reduce contraceptive protection. They act in the same population, and neither announces itself.
- When the Reason for Treatment Causes the OutcomePeople given a drug differ from those not given it - by the condition that prompted it. A 2026 Danish cohort shows the problem unusually clearly.
- Why Age Changes the CalculationThe same weight reduction carries different consequences at 75 than at 45. Lean mass, bone and nutritional intake all sit differently.
- Where a Peptide Stops Being a DrugFDA treats 40 residues or fewer as a peptide - a drug. Longer is a protein, a biologic. That single number governs how generics reach the market.
- When the Intended Effect Goes Too FarA 2026 systematic review describes gastroparesis as an under-recognised complication. It is the drug's own mechanism crossing into pathology.